Preclinical studies reveal PD-1 inhibition accelerates diabetes onset across age groups, while CTLA-4 inhibition primarily affects young non-obese diabetic mice,[45] indicating distinct roles: CTLA-4 regulates naïve T cells, whereas PD-1 controls both naïve and autoimmune T cell activation. The gene discussed is CTLA4; the disease is diabetes mellitus.